» Authors » M Schwenn

M Schwenn

Explore the profile of M Schwenn including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 148
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu J, Cross A, Baris D, Ward M, Karagas M, Johnson A, et al.
Br J Cancer . 2012 May; 106(11):1891-8. PMID: 22568968
Background: Despite many studies on diet and bladder cancer, there are areas that remain unexplored including meat mutagens, specific vegetable groups, and vitamins from diet. Methods: We conducted a population-based...
2.
Laver J, Mahmoud H, Pick T, Hutchinson R, Weinstein H, Schwenn M, et al.
Leuk Lymphoma . 2001 Nov; 42(3):399-405. PMID: 11699405
The Pediatric Oncology Group (POG) adopted a histology-based approach to the management of pediatric non-Hodgkin's lymphomas (NHL) utilizing the National Cancer Institute Working Formulation for Clinical Usage. Patients with diffuse...
3.
Waber D, Carpentieri S, Klar N, Silverman L, Schwenn M, Hurwitz C, et al.
J Pediatr Hematol Oncol . 2000 Jun; 22(3):206-13. PMID: 10864051
Purpose: The cognitive sequelae of treatment for childhood acute lymphoblastic leukemia (ALL) were compared in a group of patients who received dexamethasone during the intensification and maintenance phases of therapy...
4.
Laver J, Barredo J, Amylon M, Schwenn M, Kurtzberg J, Camitta B, et al.
Leukemia . 2000 Mar; 14(3):369-73. PMID: 10720128
Contemporary chemotherapy has significantly improved event-free survival among patients with T cell-lineage acute lymphoblastic leukemia (T-ALL). Unlike B-precursor ALL, most investigators are still using cranial radiation (CRT) and are hesitant...
5.
Hutchison R, Finch C, Kepner J, Fuller C, Bowman P, Link M, et al.
Ann Oncol . 2000 Mar; 11 Suppl 1:35-8. PMID: 10707776
Introduction: Burkitt-like lymphoma (BLL) is a provisional category of B-cell lymphoma which is morphologically intermediate between Burkitt lymphoma (BL) and large B-cell lymphoma (LBCL). The clinical significance of this morphology...
6.
Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H, et al.
J Clin Oncol . 1998 Feb; 16(2):522-6. PMID: 9469336
Purpose: Contemporary chemotherapy has significantly improved the event-free survival (EFS) among patients with T-cell disease. However, myelosuppression has been a significant adverse effect of this approach. In this study, we...
7.
Hutchison R, Banki K, Shuster J, Barrett D, DIECK C, BERARD C, et al.
Ann Oncol . 1997 Jan; 8 Suppl 1:37-42. PMID: 9187427
Background: Anaplastic lymphoma kinase (ALK) is a tyrosine kinase inappropriately expressed in lymphoid tissue involved by CD30+ anaplastic large-cell lymphoma (ALCL) with the translocation t(2;5)(p23;q35)(, which juxtaposes the nucleophosmin gene...
8.
Katz J, Hvizdala E, Shuster J, Falletta J, Schwenn M, MURPHY S
J Clin Oncol . 1993 Oct; 11(10):2054-5. PMID: 8410135
No abstract available.
9.
Kung F, Pratt C, Vega R, Jaffe N, Strother D, Schwenn M, et al.
Cancer . 1993 Mar; 71(5):1898-903. PMID: 8448755
Background: The prognosis for children with recurrent or resistant malignant solid tumors remains dismal. More effective rescue therapy is needed for these children. Methods: Between August 1987 and November 1990,...
10.
Sonis A, Tarbell N, Valachovic R, Gelber R, Schwenn M, Sallan S
Cancer . 1990 Dec; 66(12):2645-52. PMID: 2249205
Ninety-seven children who were diagnosed with acute lymphoblastic leukemia before 10 years of age and treated with chemotherapy alone, chemotherapy plus 1800-cGy cranial irradiation (RT), or chemotherapy plus 2400-cGy RT...